Tuesday, August 15, 2023 9:00:33 AM
The final 2 articles highlighted in this issue of the Medical Letter address the question of cost. The first notes the recent approval of the new bone marrow stimulatory agent eflapegrastim-xnst (Rolvedon) for the prevention of chemotherapy-induced febrile neutropenia. The agent was FDA approved based on the results of 2 randomized trials in which it demonstrated noninferiority in one trial and possible superiority in the other trial vs pegfilgrastim (Neulasta).
Although there should always be interest in discovering novel, increasingly effective, less toxic approaches to supportive care measures in cancer management, the question here is the value of such agents vs less expensive biosimilar agents employed for this purpose. One dose of eflapegrastim is said to cost $4500 compared with pegfilgrastim biosimilar costing approximately $2500. This sum is not insignificant considering the common use of bone marrow stimulatory agents by oncology practices and health care systems, as well as the financial impact on third-party payers or as increasingly mandated insurance co-pay for individual patients.
https://www.onclive.com/view/unresolved-issues-in-antineoplastic-drug-therapy-is-it-finally-time-to-address-
Recent ASRT News
- Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:05 PM
- Sig Kirk Joins Assertio Board of Directors • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Assertio to Present at LD Micro Invitational Conference in New York City • GlobeNewswire Inc. • 04/01/2024 01:00:18 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/11/2024 09:32:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:07:33 PM
- Assertio Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/11/2024 08:01:00 PM
- U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher • IH Market News • 03/11/2024 10:39:47 AM
- The Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT • PR Newswire (US) • 03/05/2024 10:45:00 AM
- Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Shareholders that lost money on Assertio Holdings, Inc.(ASRT) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/26/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:32:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:30:20 PM
- Class Action Filed Against Assertio Holdings, Inc. (ASRT) - March 5, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 02/22/2024 10:45:00 AM
- Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 02/15/2024 10:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:02:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:01:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:00:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:01:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:00:30 PM
- The Gross Law Firm Reminds Assertio Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT • PR Newswire (US) • 02/09/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Assertio Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 5, 2024 - (NASDAQ: ASRT) • PR Newswire (US) • 02/02/2024 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:00:58 PM
- The Gross Law Firm Notifies Shareholders of Assertio Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 5, 2024 - (NASDAQ: ASRT) • PR Newswire (US) • 01/26/2024 10:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM